China's Yangtze River Pharmaceutical probed for resale price maintenance
A well-known Chinese pharmaceuticals manufacturer, Yangtze River Pharmaceutical Group, is the target of an antitrust probe for resale price maintenance and could face hefty fines, MLex has learned.A well-known Chinese pharmaceuticals...To view the full article, register now.
Already a subscriber? Click here to view full article